The DOI matches its Crossref record.
Linezolid versus vancomycin for treatment of resistant Gram-positive infections in children
Abstract
BACKGROUND: Pediatric infections caused by resistant Gram-positive infections are an increasing concern with limited treatment options. Linezolid, a new oxazolidinone, is active against staphylococci, streptococci and enterococci. OBJECTIVE: To assess clinical efficacy and safety of linezolid vs.vancomycin in antibiotic-resistant Gram-positive infections in children. DESIGN Hospitalized children (birth to 12 years of age) with nosocomial pneumonia, complicated skin/skin structure infections, catheter-related bacteremia, bacteremia of unknown source or other infections caused by Gram-positive bacteria were randomized 2:1 to receive linezolid intravenously followed by oral linezolid or vancomycin and then by an appropriate oral agent. Treatment duration was 10 to 28 days. RESULTS: There were 321 patients enrolled (linezolid 219, vancomycin 102). Clinical cure rates were 79% vs.74% (P = 0.36) and 89% vs.85% (P = 0.31) for linezolid and vancomycin in intent-to-treat and clinically evaluable patients, respectively. Cure rates were similar by age and infection diagnosis. Pathogen eradication rates in microbiologically evaluable patients were high for linezolid and vancomycin, respectively, for methicillin-susceptible S. aureus (95% vs.94%; P = 0.82), methicillin-resistant S. aureus (88% vs.90%; P = 0.89) and methicillin-resistant coagulase-negative staphylococci (85% vs.83%, P = 0.87). In clinically evaluable patients, linezolid-treated patients required significantly fewer days of intravenous therapy compared with vancomycin-treated patients (8.0 +/- 4.8; 10.9 +/- 5.8 days, respectively; P < 0.001). In addition significantly fewer linezolid-treated patients had drug-related adverse events than did vancomycin-treated patients (19% vs.34%, respectively; P = 0.003). Hematologic events were uncommon and similar between treatment groups. CONCLUSIONS: Linezolid was well-tolerated and as effective as vancomycin in treating serious Gram-positive infections in children.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Waves of resistance: Staphylococcus aureus in the antibiotic era
Chambers, H. F., & DeLeo, F. R. (2009) · Nature Reviews Microbiology · doi:10.1038/nrmicro2200 · Cited by 2,718
Predictors of Mortality in Staphylococcus aureus Bacteremia
van Hal, S. J., Jensen, S. O., Vaska, V. L., Espedido, B. A., Paterson, D. L., & Gosbell, I. B. (2012) · Clinical Microbiology Reviews · doi:10.1128/cmr.05022-11 · Cited by 932
Three-Year Surveillance of Community-AcquiredStaphylococcus aureus Infections in Children
Kaplan, S. L., Hulten, K. G., Gonzalez, B. E., Hammerman, W. A., Lamberth, L., Versalovic, J., & Mason, E. O. (2005) · Clinical Infectious Diseases · doi:10.1086/430312 · Cited by 602
Self-citationStryjewski, M. E., & Chambers, H. F. (2008) · Clinical Infectious Diseases · doi:10.1086/533593 · Cited by 268
Serious Infections Caused by Methicillin‐Resistant Staphylococcus aureus
Boucher, H., Miller, L. G., & Razonable, R. R. (2010) · Clinical Infectious Diseases · doi:10.1086/653519 · Cited by 252
Metadata
- Authors
- KAPLAN, S. L., DEVILLE, J. G., YOGEV, R., MORFIN, M. R., WU, E., ADLER, S., EDGE-PADBURY, B., NABERHUIS-STEHOUWER, S., & BRUSS, J. B.
- Venue
- The Pediatric Infectious Disease Journal
- Published
- 2003-08
- Volume
- 22
- Issue
- 8
- Pages
- 677-686
- ISSN
- 0891-3668 (ISSN-L)
- OpenAlex
- W1990448757
- Cited by
- 191
- References
- 0
- FWCI
- 8.77
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Linezolid versus vancomycin for treatment of resistant Gram-positive infections in children. https://app.cochat.ai/papers/10.1097/01.inf.0000078160.29072.42
- The paper
- KAPLAN, S. L., DEVILLE, J. G., YOGEV, R., MORFIN, M. R., WU, E., ADLER, S., EDGE-PADBURY, B., NABERHUIS-STEHOUWER, S., & BRUSS, J. B. (2003). Linezolid versus vancomycin for treatment of resistant Gram-positive infections in children. The Pediatric Infectious Disease Journal. https://doi.org/10.1097/01.inf.0000078160.29072.42
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.